Hormone therapy after endometrial cancer

Endocrine-Related Cancer

Volumn 11, Issue 2, 2004, Pages 305-314

  Mueck, A O ^a   Seeger, H ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTRIOL; ESTROGEN; GESTAGEN; HYPERICUM PERFORATUM EXTRACT; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; PLANT EXTRACT; PROGESTERONE; RALOXIFENE; TIBOLONE; VENLAFAXINE;

ARTICLE; BREAST CANCER; CANCER RISK; CANCER SURVIVAL; CARDIOVASCULAR RISK; CASE CONTROL STUDY; DIABETES MELLITUS; ENDOMETRIUM CANCER; FEMALE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPERTENSION; LOW DRUG DOSE; MENOPAUSAL SYNDROME; OBESITY; OVARY POLYCYSTIC DISEASE; RECURRENCE RISK; SYSTEMATIC REVIEW;

ENDOMETRIAL NEOPLASMS; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; PROGESTERONE;

EID: 3042633628     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0110305     Document Type: Article

References (64)

1. Albertazzi P 2002 Management of hot flushes without oestrogen. Journal of the British Menopause Society 8 147-151.
2. Albrecht BH, Schiff I, Tulchinsky D & Ryan KJ 1981 Objective evidence that placebo and oral medroxyprogesterone acetate therapy diminish menopausal vasomotor flushes. American Journal of Obstetrics and Gynecology 139 631-635.
3. American Cancer Society 2002 Cancer Facts and Figures. Atlanta, GA: American Cancer Society.
4. American College of Obstetricians and Gynecologists (ACOG) 1993 Estrogen Replacement Therapy and Endometrial Cancer. Committee Opinion 126. Washington, DC: ACOG.
5. American College of Obstetricians and Gynecologists (ACOG) 2001 Hormone replacement therapy in women treated for endometrial cancer. Committee Opinion 235. International Journal of Gynecology and Obstetrics 73 283-284.
6. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland 2002 Krebs in Deutschland-Häufigkeiten und Trends, 3rd edn. Saarbrücken.
7. Baker DP 1990 Estrogen replacement therapy in patients with previous endometrial carcinoma. Comprehensive Therapy 6 35.
8. Beresford SAA, Weiss NS, Voigt LF & McKnight B 1997 Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 349 458-461.
9. Bertone E & Weiderpass E 2000 Low dose oestrogens and endometrial cancer. Review. Journal of the British Menopause Society 6 89-92.
10. Birkhäuser M, Braendle W, Keller PJ, Kiesel L, Kuhl H & Neulen J 2003 Zürcher Gesprächskreis. Frauenarzt 44 390-394.
11. Bjarnason K, Cerin A, Lindgren R & Weber T 1999. The Scandinavian Long Cycle Study Group. Adverse endometrial effects during long cycle hormone replacement therapy. Maturitas 32 161-170.
12. Bryant GW 1990 Administration of estrogens in patients with a previous diagnosis of endometrial adenocarcinoma (letter). Southern Medical Journal 83 725-726.
13. Bullock JL, Massey FM & Gambrell RD Jr 1975 Use of medroxyprogesterone acetate to prevent menopausal symptoms. Obstetrics and Gynecology 46 165-168.
14. Carr JA, Schoon PA & Look KY 1996 An atypical recurrence of endometrial carcinoma following estrogen replacement therapy. Gynecologic Oncology 7 575-580.
15. Chapman JA, DiSaia PJ, Osann K, Roth PD, Gillotte DL & Berman ML 1996 Estrogen replacement in surgical stage I and II endometrial cancer survivors. American Journal of Obstetrics and Gynecology 175 1195-1200.
16. Chlebowski RT & McTiernan A 1999 Elements of informed consent for hormone replacement therapy in patients with diagnosed breast cancer. Journal of Clinical Oncology 17 140-142.
17. Creasman WT 1999 HRT and women who have had breast or endometrial cancer. Journal of Epidemiology and Biostatistics 4 217-225.
18. Creasman WT, Henderson D, Hinshaw W & Clarke-Pearson DL 1986 Estrogen replacement therapy in the patient treated for endometrial cancer. Obstetrics and Gynecology 67 326-330.
19. Emons G (for the German Society of Senology) 2002. Hormonsubstitution nach Mammakarzinom. Eine Konsensusempfchlung. Gynäkologe 35 1114-1116.
20. Emons G & Schulz K-D 1998 Ätiologie des Endometriumkarzinoms. In Endometrium und Hormonsubstitution, pp 47-54. Eds AO Mueck & T Römer. Stuttgart: Georg Thieme Verlag.
21. Emons G, Fleckenstein G, Hinney B, Huschmand A & Heyl W 2000 Hormonal interactions in endometrial cancer. Endocrine-Related Cancer 7 227-242.
22. Emons G, Gründker C & Hanf V 2003 Are estrogens carcinogens? Gynäkologe 36 182-189.
23. Erkkola R, Kumento U, Lehmuskowski S, Mattila L & Mustonen M 2002 No increased risk of endometrial hyperplasia with fixed long-cycle hormone replacement therapy after two years. Journal of the British Menopause Society 8 155-156.
24. Farish E, Barnes JF, O'Donoghue F, Fletcher CD, Ekevall K & Hart DM 2000 The role of megestrol acetate as an alternative to conventional hormone replacement therapy. Climacteric 3 125-134.
25. German Society of Endocrinology 1988 Konsensus: Östrogen-/Gestagen- Substitution während und nach den Wechseljahren. Deutsches Ärzteblatt 85 B-1322-1325.
26. German Society of Endocrinology 1996 Konsensus: strogen-/Gestagen- Substitution während und nach den Wechseljahren. Endokrinologie- Informationen 20 122-125.
27. Glazier MG & Bowman MA 2001 A review of the evidence for the use of phytoestrogens as a replacement for traditional estrogen replacement therapy. Archives of Internal Medicine 161 1161-1172.
28. Grady D, Gebretsadik T, Kerlikowski K, Ernster V & Petitti D 1995 Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstetrics and Gynecology 85 304-315.
29. Guttuso T, Kurlan R, McDermott MP & Kieburtz K 2003 Gabapentin's effects on hot flashes in postmenopausal women: a randomised controlled trial. Obstetrics and Gynecology 101 337-345.
30. Hill DA, Weiss NS, Beresford SAA, Voigt LF, Daling JR, Stanford JL & Self S 2000 Continuous combined hormone replacement therapy and risk of endometrial cancer. American Journal of Obstetrics and Gynecology 183 1456-1461.
31. Hillard T 2000 Serving without stimulation. Journal of the British Menopause Society (Suppl 2) 6 11-13.
32. Johnson EB, Muto MG, Yanushpolsky EH & Mutter GL 2001 Phytoestrogen supplementation and endometrial cancer. Obstetrics and Gynecology 98 947-950.
33. Kenemans P 2000 Postmenopausal sex hormones and cancer of the endometrium and breast. Journal of the British Menopause Society 6 (Suppl 3) 4-9.
34. Kloosterboer HJ & Sands R 2000 Intracinology: the secret of the tissue-specificity of tibolone. Journal of the British Menopause Society 6 (Suppl 2) 23-27.
35. Lauritzen C 1993 Östrogensubstitution in der Postmenopause vor und nach behandeltem Genital- und Mammakarzinom. In Menopause und Hormonsubstitution heute, pp 76-80. Ed C Lauritzen. Basel: Aesopus Verlag.
36. Lee RB, Burke TW & Park RC 1990 Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecologic Oncology 36 189-191.
37. Liehr JG 2000 Is estradiol a genotoxic mutagenic carcinogen? Endocrine Reviews 21 40-54.
38. Loprinzi CL, Michalek JC, Quella SK, O'Fallon JR, Hatfield AK, Nelimark RA, Dose AM, Fischer T, Johnson C & Klatt NE 1994 Megestrol acetate for the prevention of hot flashes. New England Journal of Medicine 331 247-252.
39. Marsden J 2002 Hormone replacement therapy and breast cancer. Lancet Oncology 3 303-311.
40. Mikkola TS & Clarkson TB 2002 Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovascular Research 53 605-619.
41. Morrison JC, Martin DC, Blair RA, Anderson GD, Kincheloe BW, Bates GW, Hendrix JW, Rivlin ME, Forman EK, Propst MG & Needham R 1980 The use of medroxyprogesterone acetate for relief of climacteric symptoms. American Journal of Obstetrics and Gynecology 138 99-104.
42. Mueck AO & Seeger H 2002 Statins and menopausal health. Journal of the British Menopause Society 8 141-146.
43. Mueck AO & Seeger H 2003 Smoking, estradiol metabolism and hormone replacement therapy. Drug Research 1 1-11.
44. Mueck AO & Stoll K-D 2001 Opipramol bei menopausalem Syndrom als Alternative bei Kontraindikationen gegen Hormonsubstitution. In Opipramol, Sigmaligand und stimmungsaufhellendes Anxiolytikum, pp 137-146. Eds WE Müller & HJ Möller. Neu-Isenburg, Germany: LinguaMed Verlag.
45. Mueck AO, Seeger H, Haasis R, Gohlke-Bärwolf C, Schieber M, Schuchert A & Meinertz T 1999 Effect of oral vs. transdermal estradiol on cGMP during exercise in women with coronary artery disease-randomized, double-blind, placebo-controlled cross over study. Circulation 100 (Suppl 18) 1386.
46. Mueck AO, Seeger H & Wallwiener D 2002 Impact of hormone replacement therapy on endogenous estradiol metabolism in postmenopausal women. Maturitas 43 87-93.
47. Mueck AO & Wallwiener D 2003 Hormonsubstitution nach Brustkrebs. Medizinische Welt 51-56.
48. Natrajan PK, Soumakis K & Gambrell RD 1999 Estrogen replacement therapy in women with previous breast cancer. American Journal of Obstetrics and Gynecology 288-295.
49. North American Menopause Society (NAMS) 2000 The role of isoflavones in menopausal health: consensus opinion of the North American Menopause Society. Menopause 7 215-229.
50. North American Menopause Society (NAMS) 2003 Estrogen and progestogen use in the peri- and postmenopausal women: September 2003 position statement of the North American Menopause Society. Menopause 10 497-506.
51. Oehler MK, Brand A & Wain GV 2003 Molecular genetics and endometrial cancer. Journal of the British Menopause Society 9 27-31.
52. Persson I, Weiderpass E, Bergkvist L, Berström R & Schairer C 1999 Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 10 253-260.
53. Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC & Mack TM 1997 Estrogen-progestin replacement therapy and endometrial cancer. Journal of the National Cancer Institute 89 1110-1116.
54. Preventive Services Task Force 1996 Guide to Clinician Preventive Services: Report of the US Preventive Services Task Force, 2nd edn. Baltimore, MD: Williams & Wilkins.
55. Pritchard KI, Khan H & Levine M (for the Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer) 2002 Clinical practice guidelines for the care and treatment of breast cancer. 14. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer. CMAJ 166 1017-1022.
56. Quella SK, Loprinzi CL, Sloan JA, Vaught NL, DeKrey WL, Fischer T, Finck G, Pierson N & Pisansky T 1998 Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer 82 1784-1788.
57. Rabe T, Mueck AO, Deuringer FU & Runnebaum B 1997 Spacing out of progestin-efficacy, tolerability and compliance of two regimens for hormonal replacement in the late postmenopause. Gynecological Endocrinology 11 383-392.
58. Römer T & Mueck AO 1998 Endometrium und Hormonsubstitution. Stuttgart, Germany: Georg Thieme Verlag.
59. Schiff I, Tulchinsky D, Cramer D & Ryan KJ 1980 Oral medroxyprogesterone in the treatment of postmenopausal symptoms. JAMA 244 1443-1445.
60. Seeger H, Wallwiener D & Mueck AO 2003 Comparison of the effect of progesterone, medroxyprogesterone acetate and norethisterone on the proliferation of human breast cancer cells. Journal of the British Menopause Society 9 36-39.
61. Sturdee DW 2003. Is 'HRT' the correct terminology? Journal of the British Menopause Society 9 53.
62. Sturdee DW, Ulrich LG, Barlow DH, Wells M, Campbell MJ, Vessey MP, Nielsen B, Anderson MC & Bragg AJ 2000 The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy. British Journal of Obstetrics and Gynaecology 109 1392-1400.
63. Suriano KA, McHale M, McLaren CE, Li KF, Re A & DiSaja PJ 2001 Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstetrics and Gynecology 97 955-960.
64. Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergström R, Lindgren A, Correia N & Persson I 1999 Risk of endometrial cancer following estrogen replacement with and without progestins. Journal of the National Cancer Institute 91 1131-1137.